After an upswing in pharma's global reputation in 2015, its standing among patient groups has swung the other way—again.
Pressure from pharmacy benefit managers and increased competition among drugmakers are taking a big bite out of Eli Lilly's list-price hikes.
Novartis has some new data in hand that could set psoriasis med Cosentyx apart from its new competitors—big-time.
Armed with $64 million in new venture funding, San Francisco’s SutroVax is setting out to challenge the world’s biggest target in vaccines, Pfizer’s superstar…
China's Food and Drug Administration proposed changes to its foreign drug approval rules in a bid to speed new, innovative meds to market.
Johnson & Johnson CEO Alex Gorsky played down the potential fallout from U.S. politics on his company—and the rest of pharma, for that matter.
Even as the new administration is promising to sweep away some FDA practices to speed drugs to market, a new study has found that there has been a dramatic…
The PCSK9 cholesterol drugs got top billing at the American College of Cardiology meeting this year, but that doesn’t mean other studies didn’t rate.
There’s a new owl in town in the OTC allergy drug battle.
Just like the United States does, New Zealand allows DTC pharma advertising. And just like in the U.S., many doctors there would like to ban the ads.